arrow
W

Wei Shen Tan

Yale University
H指数:35
被引数:3,641

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

将临床可操作生物标志物整合到膀胱癌护理中——国际膀胱癌小组的建议

2026-08-050
PRE
Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials

对接受辅助治疗的中危非肌层浸润性膀胱癌结局的汇总分析:四项随机对照试验的合并分析

2026-07-140
PRE
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group

非肌层浸润性膀胱癌的中危风险:国际膀胱癌小组关于定义、风险分层、管理策略和临床试验设计的建议

2025-10-100
PRE
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies

低级别非肌层浸润性膀胱癌:分子景观、治疗策略及新兴疗法

2025-09-100
PRE
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies

肿瘤分期对接受保留膀胱疗法的高级别卡介苗无应答的非肌层浸润性膀胱癌患者肿瘤学结局的影响

2025-02-070
PRE
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer

序贯性膀胱内吉西他滨和多西他赛与卡介苗在卡介苗难治性非肌层浸润性膀胱癌患者中的肿瘤学结局比较

2024-12-010
PRE